Close
Virginia Kaklamani, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Virginia Kaklamani, M.D.
Dr. Kaklamani is professor of medicine in the Division of Hematology and Medical Oncology at the University of Texas Health Sciences Center San Antonio and is the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson. Dr. Kaklamani completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology/oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution. Dr. Kaklamani has also served as the associate director for clinical research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. Dr. Kaklamani has also identified several genetic mutations that link obesity and breast cancer.
Dr. Kaklamani was also named one of San Antonio’s Top Doctors for Women and San Antonio’s Top Doctors 2021.
Gender
- Female
Languages Spoken
- English
- Greek
Virginia Kaklamani | Breast Oncology
Breast Cancer is a disease we all need to fight together
-
Credentials
Credentials
Positions
- Professor of Medicine, University of Texas Health Science Center San Antonio
- Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
- A.B. Alexander Distinguished Chair in Oncology
- Leader, Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center
- Co-Director, Cancer Genetics Program, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine Hematology Oncology
Education
- Medical School: National & Kapodistrian University of Athens, Athens, Greece
- Residency: Athens University Medical School, Athens, Greece
- Graduate School: Northwestern University, Chicago, Illinois
-
Locations & Contact
Locations & Contact
Dr. Kaklamani is very, very knowledgeable, very polite. She makes you feel comfortable in the office talking about difficult topics. I would highly recommend her and appreciate her greatly. Thank you.
Patient
-
Research & Publications
Research & Publications
BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association
Waisbren J., Uthe R., Siziopikou K., Kaklamani V.
BMJ Case Rep. 2015 Jul 6;2015. pii: bcr2014208830. doi: 10.1136/bcr-2014-208830. PubMed PMID: 26150619.
National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
Daly M.B., Pilarski R., Axilbund J.E., Buys S.S., Crawford B., Friedman S., Garber J.E., Horton C., Kaklamani V., Klein C., Kohlmann W., Kurian A., Litton J., Madlensky L., Marcom P.K., Merajver S.D., Offit K., Pal T., Pasche B., Reiser G., Shannon K.M.,
J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38. PubMed PMID: 25190698
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
Kaklamani V.G., Jeruss J.S., Hughes E., Siziopikou K., Timms K.M., Gutin A., Abkevich V., Sangale Z., Solimeno C., Brown K.L., Jones J., Hartman A.R., Meservey C., Jovanovic B., Helenowski I., Khan S.A., Bethke K., Hansen N., Uthe R., Giordano S., Rosen S
Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. PubMed PMID: 26006067.
-
Clinical Trials
Clinical Trials
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT02488967
Principal Investigator
Virginia Kaklamani M.D.
NRG-BR003, A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (CTMS# 15
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH 1) Mutations (CTMS# 16-0030)
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT03329131
Principal Investigator
Virginia Kaklamani M.D.
Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy (CTMS# 17-0033)
To determine rate and severity of chemotherapy induced neuropathy in extremities treated with cold gloves and socks versus control extremities
ClinicalTrials.gov Identifier
NCT02988986
Principal Investigator
Virginia Kaklamani M.D.
Open Label, Phase II Trial Of Neoadjuvant TAK-228 Plus Tamoxifen In Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor Type 2 (HER2)-Negative Breast Cancer (CTMS# 17-0070)
This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
Molecular Analysis for Therapy Choice (MATCH) / MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, and Colorectal Adenocarcin
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT03122444
Principal Investigator
Virginia Kaklamani M.D.
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untreated Breast Cancer. (CTMS# 17-0037)
Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER TRIAL (EMERALD) CTMS#: 19-0013
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, An Anti-HER2-Antibody Drug Conjugate, Versus Ado-Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Lea
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN LA ROCHE LTD SPONSORED ATEZOLIZUMAB STUDY (IMBRELLA B)
Type of Cancer
Breast Cancer - In situ
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Th
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumabwhen given in combination with trastuzumab emtansine compared with placebo andtrastuzumab emtansine for patients with residual invasive HER2-positive breast cancerfollowing neoadjuvant taxane-based and HER2-targeted therapy including trastuzumab, whoare at high risk of disease recurrence. The primary…
ClinicalTrials.gov Identifier
NCT04849364
Principal Investigator
Virginia Kaklamani M.D.
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE) (CTMS# 21-0116)
This is a 3-arm study where placement in each arm is determined by circulating tumor DNA status. Patients with residual triple negative breast cancer disease after pre-operative therapy will be assigned to 1 of 3 Arms based on their circulating tumor DNA status and other DNA characteristics.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a
postMONARCH is a Phase 3, global, multicenter, randomized, double-blind, placebo-controlledstudy in participants with HR+, HER2- advanced or metastatic breast cancer. This study willenroll adults who experienced disease progression on a CDK4 & 6 inhibitor and an AI in thefirst-line setting or relapse on/after a CDK4 & 6 inhibitor with ET in the adjuvant setting.